Compare Stocks: MRK, AMGN, and BMY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$377.35 -1.3%	$400.37	$269.77 ▼ $447.03	$206.78B	0.43	2.46 million shs	2.27 million shs
BMY Bristol Myers Squibb	$63.53 -0.4%	$63.61	$42.52 ▼ $68.64	$130.00B	0.23	7.40 million shs	7.05 million shs
MRK Merck & Co., Inc.	$144.02 -0.5%	$136.51	$77.58 ▼ $156.92	$357.02B	0.21	10.65 million shs	8.68 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-1.34%	-13.70%	-9.33%	+6.24%	+35.49%
BMY Bristol Myers Squibb	-0.37%	-4.97%	-0.35%	+11.36%	+34.73%
MRK Merck & Co., Inc.	-0.46%	-4.22%	+8.21%	+20.97%	+71.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$377.35 -1.3%	$400.37	$269.77 ▼ $447.03	$206.78B	0.43	2.46 million shs	2.27 million shs
BMY Bristol Myers Squibb	$63.53 -0.4%	$63.61	$42.52 ▼ $68.64	$130.00B	0.23	7.40 million shs	7.05 million shs
MRK Merck & Co., Inc.	$144.02 -0.5%	$136.51	$77.58 ▼ $156.92	$357.02B	0.21	10.65 million shs	8.68 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-1.34%	-13.70%	-9.33%	+6.24%	+35.49%
BMY Bristol Myers Squibb	-0.37%	-4.97%	-0.35%	+11.36%	+34.73%
MRK Merck & Co., Inc.	-0.46%	-4.22%	+8.21%	+20.97%	+71.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.33	Hold	$381.68	1.15% Upside
BMY Bristol Myers Squibb	2.56	Moderate Buy	$66.33	4.42% Upside
MRK Merck & Co., Inc.	2.68	Moderate Buy	$151.32	5.07% Upside

Current Analyst Ratings Breakdown

Latest MRK, AMGN, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	BMY Bristol Myers Squibb	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$60.00 ➝ $65.00
9/10/2026	AMGN Amgen	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$445.00 ➝ $425.00
9/10/2026	MRK Merck & Co., Inc.	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$150.00 ➝ $172.00
9/9/2026	MRK Merck & Co., Inc.	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$127.00 ➝ $161.00
9/8/2026	AMGN Amgen	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$450.00
9/8/2026	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$400.00
9/8/2026	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$146.00 ➝ $170.00
9/4/2026	AMGN Amgen	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$400.00 ➝ $435.00
9/4/2026	MRK Merck & Co., Inc.	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$150.00 ➝ $170.00
8/25/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/25/2026	MRK Merck & Co., Inc.	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$155.00 ➝ $180.00

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$36.75B	5.55	$33.36 per share	11.31	$16.08 per share	23.47
BMY Bristol Myers Squibb	$49.19B	2.64	$8.10 per share	7.84	$9.09 per share	6.99
MRK Merck & Co., Inc.	$65.01B	5.47	$11.37 per share	12.67	$21.22 per share	6.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$16.09	23.45	15.45	2.76	22.95%	124.14%	13.18%	11/3/2026 (Estimated)
BMY Bristol Myers Squibb	$7.05B	$4.54	13.99	9.86	0.30	18.87%	66.90%	14.74%	10/29/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	115.22	14.91	6.30	4.77%	16.73%	6.13%	10/29/2026 (Estimated)

Latest MRK, AMGN, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	AMGN Amgen	$5.62	$6.29	+$0.67	$4.37	$9.43 billion	$10.05 billion
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
7/30/2026	Q2 2026	BMY Bristol Myers Squibb	$1.60	$2.04	+$0.44	$1.62	$11.74 billion	$12.97 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	2.67%	+8.27%	62.65%	14 Years
BMY Bristol Myers Squibb	$2.52	3.97%	+1.61%	55.51%	17 Years
MRK Merck & Co., Inc.	$3.40	2.36%	+5.75%	272.00%	14 Years

Latest MRK, AMGN, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.61%	9/15/2026	9/15/2026	10/7/2026
7/30/2026	AMGN Amgen	quarterly	$2.52	2.29%	8/21/2026	8/21/2026	9/11/2026
6/17/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.34%	7/2/2026	7/2/2026	8/3/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	4.44	1.37	1.13
BMY Bristol Myers Squibb	1.89	1.53	1.38
MRK Merck & Co., Inc.	1.22	1.32	1.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BMY Bristol Myers Squibb	76.41%
MRK Merck & Co., Inc.	76.07%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
BMY Bristol Myers Squibb	0.05%
MRK Merck & Co., Inc.	0.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	540.63 million	536.04 million	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.46 billion	Optionable

MRK, AMGN, and BMY Headlines

Recent News About These Companies

Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, HSBC Analyst Says

September 12 at 2:50 AM | americanbankingnews.com

Wall Street Zen Downgrades Merck & Co., Inc. (NYSE:MRK) to Hold

September 12 at 1:56 AM | americanbankingnews.com

Merck & Co., Inc. (NYSE:MRK) Lowered to Hold Rating by Wall Street Zen

September 12 at 1:23 AM | marketbeat.com

Smith Chas P & Associates PA Cpas Has $46.21 Million Stake in Merck & Co., Inc. $MRK

September 11 at 7:03 PM | marketbeat.com

7,741 Shares in Merck & Co., Inc. $MRK Bought by Talon Private Wealth LLC

September 11 at 7:03 PM | marketbeat.com

MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE

September 11 at 3:04 PM | finance.yahoo.com

Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat

September 11 at 3:04 PM | 247wallst.com

MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE

September 11 at 12:20 PM | zacks.com

Merck builds around Keytruda; prediction markets raise new risks

September 11 at 10:02 AM | pharmavoice.comP

Advanced Bioreactor Systems Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)

September 11 at 10:02 AM | finance.yahoo.com

The Manufacturers Life Insurance Company Has $266.40 Million Position in Merck & Co., Inc. $MRK

September 11 at 5:27 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Given Consensus Rating of "Moderate Buy" by Brokerages

September 11 at 4:43 AM | marketbeat.com

IPG Investment Advisors LLC Lowers Position in Merck & Co., Inc. $MRK

September 11 at 4:24 AM | marketbeat.com

Merck & Co., Inc. $MRK Shares Sold by Corient Private Wealth LP

September 11 at 3:52 AM | marketbeat.com

Leerink Partners Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

September 11 at 3:17 AM | americanbankingnews.com

Rep. Maria Elvira Salazar Buys Merck & Co., Inc. (NYSE:MRK) Stock

September 11 at 2:01 AM | marketbeat.com

Congresswoman Bets on Elon Musk, Warren Buffett: Here's the Latest Stock Transactions

September 10 at 7:03 PM | benzinga.com

Merck (MRK) Dips More Than Broader Market: What You Should Know

September 10 at 6:50 PM | zacks.com

Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?

September 10 at 6:43 PM | trefis.comT

Merck (MRK) Dips More Than Broader Market: What You Should Know

September 10 at 6:43 PM | finance.yahoo.com

Merck & Co., Inc. (NYSE:MRK) Trading Down 1.9% - Should You Sell?

September 10 at 5:39 PM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MRK, AMGN, and BMY Company Descriptions

Amgen NASDAQ:AMGN

$377.35 -5.12 (-1.34%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$377.82 +0.47 (+0.13%)

As of 09/11/2026 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Bristol Myers Squibb NYSE:BMY

$63.52 -0.23 (-0.35%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$63.54 +0.02 (+0.02%)

As of 09/11/2026 07:55 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Merck & Co., Inc. NYSE:MRK

$144.02 -0.69 (-0.47%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$144.28 +0.26 (+0.18%)

As of 09/11/2026 07:57 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRK, AMGN, and BMY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRK, AMGN, and BMY Earnings

Compare Dividends

Latest MRK, AMGN, and BMY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRK, AMGN, and BMY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MRK, AMGN, and BMY Company Descriptions

Amgen NASDAQ:AMGN

Bristol Myers Squibb NYSE:BMY

Merck & Co., Inc. NYSE:MRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRK, AMGN, and BMY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRK, AMGN, and BMY Earnings

Compare Dividends

Latest MRK, AMGN, and BMY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRK, AMGN, and BMY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MRK, AMGN, and BMY Company Descriptions

Amgen NASDAQ:AMGN

Bristol Myers Squibb NYSE:BMY

Merck & Co., Inc. NYSE:MRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools